

www.fluencecorp.com

Fluence Corporation (ASX: FLC) Q3 2020 Summary

# First nine months 2020 Key Highlights





- Employees, partners and customers kept safe during global pandemic
- Operating revenue up 95% to \$72.9m\*
- SG&A continued to decline, down ~22%
- EBITDA positive, and expected to remain positive
- Recurring revenue up 63% to \$5.7m from BOOT and O&M contracts
- Smart Products Solutions (SPS) growth of 41% year-to-date ⇒incl. China growth of 39%
- SPS New Orders up 22% year-to-date
- Achieved Conditions Precedent, received Notice-to-Proceed and €23.1m Advance Payment for the Ivory Coast Project
- Secured debt facility of \$20m from Upwell Water
- Total cash flow positive US \$4.3m for the first nine months, cash balance of \$31.2m at September 30, 2020
- Backlog of \$215m as at September 30, 2020 (\$156m related to the Ivory Coast project)

### **Ivory Coast Project: Construction Commences**



Fluence has announced final conditions precedent for the €165 million (approx. US\$190 million) Ivory Coast water treatment plant ("Project") have been met

The Ivory Coast Government finance facility will now begin to fund contractual payments for the Project to Fluence.

#### €23.1 million Advance Payment received

Construction is commencing of the 150,000 m3/day water treatment plant outside of Abidjan to be erected within 24 months

Additional milestone payments are expected in Q4/2020

Opportunity to bid on long-term operations & maintenance contract after construction has been completed





# Q3 Summary



Ivory Coast Project conditions precedent met, notice-to-proceed issued, construction commencing and advance payment received
Revenue of US\$15.6M, up 13% on pcp and up 50% vs Q2 2020
Reduction of SG&A by more than 16% on pcp and down 22% year-to-date on pcp
Gross bookings of US\$7.5M
Cash balance of US\$31.2M as at 30 September 2020
Total cash flow positive \$11.1M in Q3
Additional payments from the Ivory Coast Project expected in Q4
FY2020 Public Guidance reaffirmed:
✓ Smart Products Solutions US\$32.0M
✓ Recurring revenue US\$9.0M

✓ EBITDA profitability

# World-Class Water and Wastewater Treatment Technology Company



Only global, pure play company delivering standardised, pre-engineered water and wastewater treatment solutions focused on the decentralized market

#### Fluence Overview

- Provides water and wastewater treatment solutions across three complementary segments
  - Smart Products Solutions (SPS): Wastewater treatment solutions leveraging patented, proprietary Membrane Aerated Biofilm Reactor (MABR) technology in addition to water treatment solutions
    - Rapid solutions focused on decentralized applications
  - Custom-Engineered Solutions (CES): Turn-key projects on a larger scale offering fully-customized solutions
  - Recurring Revenue (RR): Build, Own, Operate and Transfer (BOOT) and complete range of Operations & Maintenance (O&M), aftermarket sales & spare part sales
- Well-positioned to capture substantial and growing global addressable market as shift towards decentralized, pre-engineered solutions as population growth, water scarcity and environmental threats accelerate





# Disclaimer



This presentation has been prepared by Fluence Corporation Limited (ASX: FLC). All currencies quoted as "\$" are US dollars unless otherwise specified.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management. In particular, the COVID-19 pandemic continues to cause disruption in all of the geographies in which the Company operates, slowing down new orders as sales conversion has become more difficult without face to face meetings. The full extent and economic impact of COVID-19 remain unknown. Although the Company believes that the expectations reflected in and the assumptions underlying the forward looking statements included in this presentation are reasonable, readers are cautioned not to place undue reliance on them, as the Company cannot give any assurance that the results, performance or achievements covered by the forward-looking statements will actually occur.

This presentation should not be considered as an offer or invitation to subscribe for or purchase any shares in FLC or as an inducement to make an offer or invitation to subscribe for or purchase any shares in FLC. No agreement to subscribe for securities in the FLC will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation. This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for informational purposes only and does not constitute an offer or invitation to apply for any securities, including in any jurisdiction where, or to any person to whom, such an offer or invitation would be unlawful.

To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation. Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information.